Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults

• Published in: The New England journal of medicine Vol. 386; no. 22; pp. 2097 - 2111
• Main Authors: Dai, Lianpan, Gao, Lidong, Tao, Lifeng, Hadinegoro, Sri R., Erkin, Musabaev, Ying, Zhifang, He, Peng, Girsang, Rodman T., Vergara, Hugo, Akram, Javed, Satari, Hindra I., Khaliq, Tanwir, Sughra, Ume, Celi, Ana P., Li, Fangjun, Li, Yan, Jiang, Zhiwei, Dalimova, Dilbar, Tuychiev, Jaloliddin, Turdikulova, Shahlo, Ikram, Aamer, Flores Lastra, Nancy, Ding, Fan, Suhardono, Mahendra, Fadlyana, Eddy, Yan, Jinghua, Hu, Zhongyu, Li, Changgui, Abdurakhmonov, Ibrokhim Y., Gao, George F.
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 02.06.2022
• Subjects: Adult; Adverse events; Aluminum; Aluminum hydroxide; Antigens; Clinical trials; Coronavirus; Coronaviruses; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Double-Blind Method; Humans; Immunogenicity; Infectious Disease; Informed consent; Original; Pandemics; Placebos; Proteins; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Vaccination; Vaccine efficacy; Vaccines; Viral Infections; Uzbekistan; China; Indonesia

ZF2001 contains a tandem-repeat dimeric receptor-binding domain of the SARS-CoV-2 spike protein with aluminum hydroxide adjuvant. In a phase 3 trial, 28,904 participants in five countries were randomly assigned to receive three doses of ZF2001 or placebo. After 6 months of follow-up, efficacy was 76...